Available Technologies

No technologies match these criteria.
Schedule UC TechAlerts to receive an email when technologies are published that match this search. Click on the Save Search link above

Find technologies available for licensing from UCSF.

Antiviral Compounds for HIV and Other Viral Infections

This invention identifies a novel class of HIV inhibitors targeting RNA-protein interactions.

FLT3 Mutations Associated with AC220 Drug Resistance in AML Patients

This invention provides methods for identifying acute myeloid leukemia (AML) patients that have an increased likelihood of a relapse following treatment with AC220.

Versatile Labeling of Protein N-Termini for Site-specific Bioconjugation

Improved subtiligase variants allow broad and versatile site-specific chemical modification or conjugation of proteins on their N-termini.

NOVEL SMALL MOLECULE COMPOUNDS AND TARGET FOR TREATMENT OF AIRWAY HYPERRESPONSIVENESS IN ASTHMA

Novel small molecule compounds that modulate a new target for the treatment of asthma. 

Novel Small Protein Inhibitors for Rapid and Controllable CRISPR-Cas9 Interference

This invention identifies a novel class of natural protein-based inhibitors of CRISPR-Cas9, which could eliminate off-target effects of Cas9-mediated gene editing. It also presents an attractive antibiotic strategy and a potential biodefense agent against CRISPR bioterror threat.

Retractable Step Cannula For Brain Delivery Of Therapeutics

An adjustable step cannula to minimize therapeutic agent leakage and maximize on-target drug delivery. This new cannula design improves brain drug delivery over current fixed-length step cannulas.

Method And System For Diagnosing And Training Cognitive Fitness Via Rhythmic Engagement

This invention is a novel method to diagnose and improve cognitive function through an adaptive training program that incorporates rhythmic engagement with computer-based game mechanics.

Novel Radiotracers for Imaging Glucocorticoid Receptor in Treatment-resistant Cancer Patients

UCSF researchers have invented novel radiotracers that allow imaging of glucocorticoid receptor (GR) expression using positron emission tomography (PET) in patients with treatment-resistant solid cancer, including prostate, breast, ovarian and lung cancer.